[ { "id": 674, "name": "TAXA Biotechnologies", "slug": "taxa-biotechnologies", "former_names": [ "Glowing Plant" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.taxa.com", "all_locations": "San Francisco, CA, USA", "long_description": "The TAXA platform has been specifically designed to enable anyone to perform metabolic engineering of plants without stepping into a lab. We provide access to protein engineering, DNA assembly, transient experiments and stable transformation as a service. The best thing is that anything \"Powered by TAXA\" is designed to be free from expensive regulatory approval, meaning the products are available for sale or distribution to consumers in the United States immediately after they are developed. For a detailed list of the experiments which can be run on our platform please see the Services page.\r\n\r\nOur vision is a world where bio-engineering is as easy and commonplace as mobile application development is today. Game-changing technologies, like genetic engineering, should not be the exclusive preserve of large corporations and a wealthy elite. Democratizing the tools of creation enables anyone, anywhere, to genetically engineer plants and will unleash a wave of creativity to power an environment where ultimately what we create is limited only by our imagination. The TAXA platform is our next step in the realization of that dream\r\n\r\nWe are also the team behind the first synthetic biology crowdfunding project, raising $484k on Kickstarter to make real glowing plants: www.glowingplant.com", "one_liner": "We enable cheaper, faster, and better genetic engineering of plants.…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Consumer Health and Wellness", "launched_at": 1398907752, "tags": [ "Agriculture", "Genetic Engineering", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2014", "status": "Inactive", "industries": [ "Healthcare", "Consumer Health and Wellness" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/taxa-biotechnologies", "api": "https://yc-oss.github.io/api/batches/summer-2014/taxa-biotechnologies.json" }, { "id": 1097, "name": "Lygos", "slug": "lygos", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.lygos.com", "all_locations": "San Francisco, CA, USA", "long_description": "Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production.", "one_liner": "Lygos engineers yeast to convert sugar into high-value industrial…", "team_size": 55, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1451966715, "tags": [ "Synthetic Biology", "Climate", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/lygos", "api": "https://yc-oss.github.io/api/batches/winter-2016/lygos.json" }, { "id": 1513, "name": "Solugen", "slug": "solugen", "former_names": [ "Solugen", "Bioperoxide" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8d4235cadbab6a51a7bfa10e7b2877bdb12a26fe.png", "website": "https://solugen.com/", "all_locations": "Houston, TX, USA", "long_description": "Solugen is decarbonizing the chemistry of everyday life with enzymes and innovative metal catalysts. Our new to the world Bioforge platform technology can produce high value chemical goods that are biobased and carbon negative, at cost on par with current technologies. We are making sustainable chemistry accessible to all living things, to ensure a prosperous world exists for generations.\r\n", "one_liner": "Decarbonizing the chemicals industry.", "team_size": 200, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1478579436, "tags": [ "Manufacturing", "Climate", "ClimateTech", "Biotechnology", "Industrial" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": true, "url": "https://www.ycombinator.com/companies/solugen", "api": "https://yc-oss.github.io/api/batches/winter-2017/solugen.json" }, { "id": 1967, "name": "Mytos", "slug": "cytera-cellworks", "former_names": [ "HackScience", "Cytera CellWorks" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/47b55852a1fff0b5b096b7decf0a07ed6cdb0636.png", "website": "https://www.mytos.bio", "all_locations": "London, England, United Kingdom", "long_description": "Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks.\r\n\r\nLast year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale.\r\n\r\nMytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.", "one_liner": "Robotic human cell manufacturing", "team_size": 26, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1525313281, "tags": [ "Hardware", "IoT", "Biotech", "Automation", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/cytera-cellworks", "api": "https://yc-oss.github.io/api/batches/summer-2018/cytera-cellworks.json" }, { "id": 12085, "name": "Volta Labs, Inc.", "slug": "volta-labs-inc", "former_names": [ "Volta Labs Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/373e91d473569c304899f7cec638ddc0b46d10d6.png", "website": "http://voltalabs.com", "all_locations": "Cambridge, MA, USA", "long_description": "Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology.\r\n\r\nAs a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality.\r\n\r\nOur HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta. ", "one_liner": "Unlocking the utility of genomics for the world.", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1607278601, "tags": [ "Hard Tech", "Hardware", "Robotics", "Genomics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": true, "question_answers": true, "url": "https://www.ycombinator.com/companies/volta-labs-inc", "api": "https://yc-oss.github.io/api/batches/winter-2019/volta-labs-inc.json" }, { "id": 13346, "name": "UrbanKisaan", "slug": "urbankisaan", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/46e8aa32e04a21d9a5ef18ccaae02b6b9ddea65d.png", "website": "https://www.urbankisaan.com", "all_locations": "Hyderabad, Telangana, India", "long_description": "UrbanKisaan is an AI-for-plant-biology company. We build foundation models and the physical infrastructure that trains them.\r\n\r\nShipping a single new seed variety takes about ten+ years. Two on germplasm, three on crosses and selection, three or four on field trials, one on regulatory. Inside that decade, prediction and experiment never properly meet. DNA is abundant, phenotype data is scarce and unpaired, and the cycle never trains itself.\r\n\r\nWe closed that loop.\r\n\r\nThree foundation models cover the upstream science. \r\n\r\nAadi is a 48-layer transformer trained from scratch on the public and proprietary corpus of plant genomes; it reads plant DNA and ranks variants before any wet-lab spend. \r\n\r\nJeeva is the genotype-to-phenotype model that turns a seed and a target environment into yield, flowering, maturity, and height with confidence intervals plus per-locus attribution. \r\n\r\nAkash is the geospatial backbone - it maps every pixel of every field to crop class and growing condition.\r\n\r\nTwo pieces of physical infrastructure close the downstream half. \r\n\r\nGeneRush is a controlled-environment chamber engineered for speed: extended photoperiod, optimized temperature, integrated phenomics. Wheat reaches anthesis in 38 days. Breeding programs run 4–6 generations a year instead of 1–2. \r\n\r\nGrowRush takes that same chamber to commercial production scale, where every harvest is also a labelled phenotype training pair flowing back to Jeeva. The unit is paid for by what it grows; the science works because the unit is identical to the chamber the AI was trained on.\r\n\r\nEvery cycle produces proprietary genotype-to-phenotype data the next generation of models needs. The ten-year breeding cycle compresses toward three. We are already commercial", "one_liner": "Foundation models and autonomous chambers for plant biology", "team_size": 53, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1583951636, "tags": [ "Biotech", "Agriculture", "AI", "Sustainable Agriculture", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Industrials", "Agriculture" ], "regions": [ "India", "South Asia" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/urbankisaan", "api": "https://yc-oss.github.io/api/batches/winter-2020/urbankisaan.json" }, { "id": 24705, "name": "Sensible Biotechnologies", "slug": "sensible-biotechnologies", "former_names": [ "Genbiotics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/45d14c57e3b4e2739c65c0bb84a511608548ffa2.png", "website": "https://sensible.bio", "all_locations": "Oxford, England, United Kingdom", "long_description": "The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.", "one_liner": "Unlocking the next generation of mRNA medicines", "team_size": 24, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1680519323, "tags": [ "Synthetic Biology", "Biotech", "Manufacturing", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/sensible-biotechnologies", "api": "https://yc-oss.github.io/api/batches/summer-2021/sensible-biotechnologies.json" }, { "id": 24795, "name": "SFA Therapeutics", "slug": "sfa-therapeutics-inc", "former_names": [ "SFA Therapeutics, Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png", "website": "https://sfatherapeutics.com/", "all_locations": "Philadelphia, PA, USA", "long_description": "SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.", "one_liner": "Regulating the immune system to block cancer & autoimmune diseases", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624038758, "tags": [ "AI-powered Drug Discovery", "Anti-Aging", "Biotech", "Health & Wellness", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": true, "question_answers": true, "url": "https://www.ycombinator.com/companies/sfa-therapeutics-inc", "api": "https://yc-oss.github.io/api/batches/summer-2021/sfa-therapeutics-inc.json" }, { "id": 25449, "name": "Alixia", "slug": "alixia", "former_names": [ "Guided Clarity" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png", "website": "http://www.alixia.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our compounds disrupt the metabolic and\r\ninflammatory triggers in both cancer and quasi-cancerous\r\ncells in the tumor microenvironment. By impacting multiple cell\r\ntypes, we are enabling effective, lasting cancer treatments.", "one_liner": "Targeting the Tumor Ecosystem to address cancer drug resistance.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1648247483, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/alixia", "api": "https://yc-oss.github.io/api/batches/winter-2022/alixia.json" }, { "id": 26427, "name": "Eugit Therapeutics", "slug": "eugit-therapeutics", "former_names": [ "EUGIT Tx", "EUGIT Therapeutics", "Eugit", "Eugit Therapeutics Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "website": "http://www.eugittx.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\r\n\r\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).", "one_liner": "Enabling Tissue Targeting of Therapies", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656718658, "tags": [ "Cell Therapy", "Synthetic Biology", "Therapeutics", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/eugit-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2022/eugit-therapeutics.json" }, { "id": 29475, "name": "Evolvere BioSciences", "slug": "evolvere-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/dd3489b7e5a5f2d3f7cc49de65917a83134da0a3.png", "website": "https://www.evolverebiosciences.com/", "all_locations": "Oxford, England, United Kingdom", "long_description": "🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. \r\n\r\n☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. \r\n\r\n🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️.\r\n\r\nWe are a team of biochemists and evolutionary biologists who met at the University of Oxford. ", "one_liner": "Making Next-Generation Antibiotics that Outpace Bacterial Evolution", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1723833827, "tags": [ "AI-powered Drug Discovery", "Artificial Intelligence", "Biotech", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/evolvere-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2024/evolvere-biosciences.json" }, { "id": 29959, "name": "Uncommon Therapeutics", "slug": "uncommon-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/791a2a1e71f62bafa47311d3711d9cab4712eea4.png", "website": "https://uncommontherapeutics.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.", "one_liner": "A Disease Focused Biotech, Building Multiple Billion Dollar Drugs", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1740166772, "tags": [ "Gene Therapy", "CRISPR", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2025", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/uncommon-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2025/uncommon-therapeutics.json" }, { "id": 30673, "name": "Nexa Labs", "slug": "nexa-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/489fd97ad45ee1d6d874c7a99792bf1552ebddc2.png", "website": "https://nexa.farm/", "all_locations": "San Francisco, CA, USA", "long_description": "Nexa is developing the solution for cattle monitoring, leveraging implantable microchips that collect more comprehensive biometrics than anything else on the market. Our accompanying AI-driven animal health engine empowers farmers with early disease detection, reproductive insights, GPS tracking, and more. \r\n\r\nWe're saving farmers time and money while collecting the world's largest cattle health dataset. We believe that cattle farming should be a science, not an art - this will secure the world's food supply and increase economic output that billions of people depend on.", "one_liner": "Implantable microchips and AI for cattle monitoring", "team_size": 3, "industry": "Industrials", "subindustry": "Industrials -> Agriculture", "launched_at": 1755009056, "tags": [ "Livestock Health", "Medical Devices", "Agriculture", "AI", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2025", "status": "Acquired", "industries": [ "Industrials", "Agriculture" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": true, "url": "https://www.ycombinator.com/companies/nexa-labs", "api": "https://yc-oss.github.io/api/batches/summer-2025/nexa-labs.json" }, { "id": 30856, "name": "Scoop", "slug": "scoop", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/70fc9c8245a9de2b245841faf07e0530dd3f51a1.png", "website": "https://scooplabs.ai", "all_locations": "San Francisco, CA, USA", "long_description": "We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.", "one_liner": "Automating regulatory submissions for life sciences", "team_size": 2, "industry": "B2B", "subindustry": "B2B", "launched_at": 1762725446, "tags": [ "Artificial Intelligence", "B2B", "Biotech", "Compliance", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2025", "status": "Active", "industries": [ "B2B" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/scoop", "api": "https://yc-oss.github.io/api/batches/fall-2025/scoop.json" }, { "id": 31276, "name": "Ritivel", "slug": "ritivel", "former_names": [ "Ritivel", "ritivel" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/20339e5cb76cdfb65db692fb1ab38e8c6f710609.png", "website": "https://www.ritivel.com", "all_locations": "San Francisco, CA, USA", "long_description": "Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Our AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster.\r\n\r\nEvery month a drug is delayed from reaching the market costs pharma companies ~$45M in lost revenue and more importantly, delays treatment for thousands of patients who need it. Yet regulatory teams are stuck in a painful, months-long process: synthesizing thousands of pages of clinical data, hunting through SharePoint folders for the right documents, chasing colleagues for missing inputs, and manually drafting submissions.\r\n\r\nRitivel deploys AI agents that transform how regulatory teams work. Our agents generate comprehensive first drafts directly in Microsoft Word, following FDA formatting requirements and pulling from your existing clinical data and prior submissions. Every data point includes citations linked back to the original source, so reviewers can verify with one click. Connected to SharePoint and Veeva, our agents automatically source the right documents. Integrated with Outlook, they handle reminder emails and follow-ups automatically.\r\n\r\nWe're engineers who previously built AI copilots at Microsoft Research. After 50+ conversations with pharma professionals, we discovered the critical bottleneck in regulatory submissions and built Ritivel to solve it. ", "one_liner": "AI-native platform for Life-Sciences Documentation ", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1768402832, "tags": [ "Generative AI", "Compliance", "Enterprise Software", "Regtech", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2026", "status": "Active", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ritivel", "api": "https://yc-oss.github.io/api/batches/winter-2026/ritivel.json" }, { "id": 31532, "name": "Atlas Discovery", "slug": "atlas-discovery", "former_names": [ "Rhizome Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6e6c174c3a8e56844bf81efbc8b8532b4e509f73.png", "website": "https://atlasdiscovery.bio", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "Discovering the atlas of disease biology using virtual cells.", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1782247231, "tags": [ "AI-powered Drug Discovery", "Drug discovery", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2026", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/atlas-discovery", "api": "https://yc-oss.github.io/api/batches/summer-2026/atlas-discovery.json" } ]